Pharma BD Deal Intelligence

Pamplona Capital Management, LLP / PAREXEL International Corporation

2017 · Take-Private · $5.0B · Complete

CALLED IT — OFF BY 15

A PE take-private that worked exactly as designed: bought for ~$5.0B in 2017, sold for $8.5B in 2021 — a ~70% value gain in four years plus successful bolt-on M&A along the way.

Full analysis, sources & comparables →

The coverage arc

Jun 20, 2017 BioPharma Dive Neutral

BioPharma Dive framed the take-private as the latest in a wave of CRO consolidation, contextualizing it alongside the QuintilesIMS and INC/inVentiv mergers and…

Jun 20, 2017 FierceBiotech Neutral

FierceBiotech highlighted the activist-led process that culminated in the Pamplona deal, noting Starboard, Jana and Corvex pressure pushed PAREXEL to explore a…

Jul 02, 2021 FierceBiotech Bullish

Pamplona's 2021 exit at $8.5B to EQT and Goldman Sachs Asset Management vindicated the original take-private thesis, with FierceBiotech noting the 70% gain on…

Source summaries from our enrichment pipeline; follow links for originals.

All 5 sources with sentiment breakdown →

PAREXEL agreed to be taken private by Pamplona Capital for $88.10/share in cash, transaction valued at approximately $5B and representing a 27.9% premium over the May 5, 2017 unaffected closing price. PAREXEL provides full-service drug development outsourcing including clinical trials, regulatory consulting and reimbursement strategy. Transaction closed September 2017.

Did it work? Outcome assessment

A PE take-private that worked exactly as designed: bought for ~$5.0B in 2017, sold for $8.5B in 2021 — a ~70% value gain in four years plus successful bolt-on M&A along the way.

Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive

Key facts

Related deals — scored

DealYearValueOutcome
Pamplona Capital Management, LLP / PAREXEL International Corporation (this deal)2017$5.0B90
Watson Pharmaceuticals (Actavis Inc.) / Actavis plc2012$5.9B97
Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital)2013$1.3B91
Stryker Corporation / MAKO Surgical Corp.2013$1.6B91
Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc.2016$17.6B91
DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products2013$2.6B90
Thermo Fisher Scientific Inc. / Patheon N.V.2017$7.2B89

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →